<DOC>
	<DOCNO>NCT02019030</DOCNO>
	<brief_summary>The purpose observational study evaluate outcome use PlasmaButton electrode treatment Benign Prostatic Hyperplasia ( BPH ) anticoagulation medication .</brief_summary>
	<brief_title>Treatment Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using PlasmaButton Vaporization Electrode</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Men obstructive symptom due benign prostatic hyperplasia also anticoagulant regimen . Anticoagulant regiment include : Aspirin 81mg , Aspirin 325mg , Adenosine diphosphate ( ADP ) receptor inhibitor , Cilostazol , Dabigatran , Dipyridamole , Warfarin . The patient stable dosage regimen least 3 month . Maximum flow rate &lt; 15ml/s uroflowmetry . International Prostate Symptom Score ( IPSS ) â‰¥10 . Patients coagulopathy , INR exceed 3 . Anticoagulation dose change within 3 month surgery . Patients medically clear undergo surgery medical reason . Patients neurogenic bladder ( bladder affect due neurologic cause ) . Urethral stricture , obstruction due stricture . Suspected bladder prostate cancer . Prostate size great 80 cc .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>benign prostatic hyperplasia</keyword>
	<keyword>Transurethral vaporization prostate</keyword>
</DOC>